Jiangsu Hengrui Medicine Co., Ltd. (SHSE: 600276) is expected to saw earnings per share (EPS) of CNY 1.29, CNY 1.54, and CNY 1.82 in 2009, 2010, and 2011, respectively.

Its dynamic price to earnings (P/E) ratio is predicted to be 32 times, 27 times, and 23 times in the three years. And the company is given a "buy" rating, with a target price of CNY 45.1.

In 2008, sales revenue in the company reached NCY 2.4 billion, growing 20.08% over the previous year; gross profits arrived at CNY 1.991 billion, rising 20.75% over a year earlier; net profit hit CNY 423 million, due to a sharp drop in fair value, up 1.97% over the previous year; net profit deducting non-recurring profit and loss was CNY 570 million, surging 100.06% over the previous year.

The leaping profits are mainly attributed to that the growth in each sales region surpassed 20% last year and the major business performed well.